Experimental combo aims to boost Radiation's punch against returning lung tumors
NCT ID NCT04505267
First seen Nov 11, 2025 · Last updated Jun 18, 2026 · Updated 26 times
Summary
This early-stage study tests a drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with a second round of radiation for people whose non-small cell lung cancer has returned and cannot be surgically removed. The main goal is to find the safest dose and check for side effects in about 34 participants. The approach aims to kill more tumor cells without harming nearby healthy tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.